(UroToday.com) Following two presentations examining long-term outcomes for patients with testicular cancer in the Prostate, Testicular, and Penile Oral Abstract session at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Daneshmand summarized these data and considered both the good and bad that has accompanied the progress made in testis cancer over the past decades.
Alicia Morgans: Hi. My name is Alicia Morgans and I’m a GU Medical Oncologist and an Associate Professor of Medicine at Northwestern University in Chicago in the US. I’m so excited to have here with me today, a good friend and colleague Dr. Neeraj Agarwal, who is a Professor of Medicine and a GU Medical […]
(UroToday.com) Pembrolizumab was approved for cisplatin-ineligible patients with untreated advanced urothelial carcinoma based on initial results of the phase 2 KEYNOTE-052 study, which showed an objective response rate of 24%.1 Updated results after two years of follow-up were consistent, showing an objective response rate of 29%.2 At the 2021 ASCO annual meeting, Dr. Peter O’Donnell and […]
(UroToday.com) Variation in prostate cancer incidence, mortality and outcomes between racial and ethnic groups has been wide recognized for many years. Men of African Ancestry experience the greatest burden of disease, due to a presumed interplay of socioeconomic factors, environmental exposures, and biologic/epigenetic phenomena. However, the causes underlying these differences is much less well understood. […]
(UroToday.com) Variation in prostate cancer incidence, mortality, and outcomes between racial and ethnic groups has been widely recognized for many years. However, the causes underlying these differences is much less well understood. Certainly, work examining prostate cancer outcomes in equal access health care systems has demonstrated that that disparity in access to care contributes.
(UroToday.com) The disease natural history of patients with localized prostate is varied – while some men will have an indolent course without treatment, others progress quickly in spite of aggressive therapy. While clinical data, including patient demographics, prostate specific antigen levels, Gleason score, and tumor stage, among others, provide prognostic information, they remain suboptimal as they do […]
(UroToday.com) Following three presentations regarding novel treatment approaches for first-line treatment of patients with metastatic hormone-sensitive prostate cancer in the Prostate, Testicular, and Penile Oral Abstract session at the 2021 American Society of Clinical Oncology Annual Meeting, Dr. Lisa Horvath provided a discussant overview of these data and the rapidly moving disease space of metastatic hormone-sensitive […]
(UroToday.com) Beginning with the introduction of docetaxel for metastatic castration resistant prostate cancer (mCRPC) in 2004, there has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer. Following developments in the mCRPC disease space, many of the same treatments have now been adopted in patients with metastatic castration sensitive disease […]
(UroToday.com) Inhibition of poly(ADP-ribose) polymerase (PARP) is synthetically lethal in cells with homozygous deletions, deleterious alterations, or both, in DNA damage response genes involved either directly or indirectly in homologous recombination repair. PARP inhibitors have recently been approved for the treatment of mCRPC, including both rucaparib and olaparib in May 2020. TALAPRO-1 is the first […]
(UroToday.com) The availability of multiple treatments for metastatic castration-resistant prostate cancer (mCRPC) mandates the need to identify, as well as validate, prognostic and predictive factors applicable to clinical practice. Given the complexity of therapeutic decision-making in these patients, there is a need to determine which patients would be most likely to benefit from a given treatment […]
